12-Month Lobbying Summary - In-house Corporation

• Subject matter details in previous versions

  Details Regarding the Identified Subject Matter

  Subject matters	Details	Categories
  Subject matters were not required to be associated with subject matter details when this content was submitted	Advocacy to maintain and increase funding for the National Immunization Strategy and discussions on vaccine procurement.	Grant, Contribution or Other Financial Benefit, Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Consider amendments to the Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of potential importation legislation in the United States.	Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Discussions around the World Trade Organization consideration of a TRIPS Patent Waiver	Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Discussions on the procurement of a COVID19 vaccine and therapy	Grant, Contribution or Other Financial Benefit
  Subject matters were not required to be associated with subject matter details when this content was submitted	Engage the Federal Government on Health Canada’s Regulatory Innovation Agenda (Agile Licensing Modernization) to discuss opportunities for further harmonization; flexibility and predictability in the new regulatory framework being develop and its linkage to pillar 5 of the Biomanufacturing and Life Sciences Strategy.	Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Health Canada’s policies, program and guidelines related to the management, prevention, mitigation and notification of drug shortages and discussion on COVID19 potential impacts	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Monitoring and engaging on the Government’s commitment to create a national strategy for rare diseases; the Canadian Drug Agency; and the development of a pharmacare legislation.	Legislative Proposal, Bill or Resolution, Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's life sciences & biomanufacturing strategy	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Monitoring and engaging the Government and Parliamentarians on the House of Commons Standing Committee on Public Accounts (PACP) motion related to the discloser on vaccine contracts	Legislative Proposal, Bill or Resolution
  Subject matters were not required to be associated with subject matter details when this content was submitted	Patented Medicine Prices Review Board (PMPRB) amendments to the Patented Medicines Regulations and the related proposed guidelines.	Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Agency for Drugs and Technologies in Health (CADTH)/Common Drug Review as well as the review times and processes conducted by Health Canada for the purpuse of obtaining a notice of compliance.	Policies or Program, Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability.	Policies or Program

  Subject matters in previous versions

  • Consumer Issues
  • Economic Development
  • Government Procurement
  • Health
  • Industry
  • Intellectual Property
  • International Relations
  • International Trade
  • Labour
  • Regional Development
  • Research and Development
  • Science and Technology
  • Taxation and Finance

  Subject matters added through a communication report:

  • Federal-Provincial Relations

Government Institutions

• Atlantic Canada Opportunities Agency (ACOA)
• Canada Border Services Agency (CBSA)
• Canada Economic Development for Quebec Regions
• Canada Revenue Agency (CRA)
• Canadian Institutes of Health Research (CIHR)
• Employment and Social Development Canada (ESDC)
• Finance Canada (FIN)
• Global Affairs Canada (GAC)
• Health Canada (HC)
• House of Commons
• Indigenous Services Canada (ISC)
• Innovation, Science and Economic Development Canada (ISED)
• Intergovernmental Affairs Secretariat (IGA)
• Justice Canada (JC)
• National Defence (DND)
• Patented Medicine Prices Review Board (PMPRB)
• Prime Minister's Office (PMO)
• Privy Council Office (PCO)
• Public Health Agency of Canada (PHAC)
• Public Services and Procurement Canada (PSPC)
• Senate of Canada
• Transport Canada (TC)
• Treasury Board Of Canada Secretariat (TBS)
• Veterans Affairs Canada (VAC)

Communication techniques

Communication techniques that have been used or are expected to be used in the course of the undertaking:

• Written communication
• Grass-roots communication
• Oral communication
• Arrange one or more meetings

Senior Officers whose lobbying activities represent less than 20% of their Duties

• Najah Sampson, President | No public offices held
• Jonathan Cullen, Vice-President, Legal Affairs & General Counsel | No public offices held
• Karine Grand-Maison, Vice President, Access & Government Relations | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

• Steven Hogue, Director, Global Policy and Public Affairs (Canada) | Public offices held